Influence of filtering on the effective concentration and sterility of a 2% cyclosporine ophthalmic solution: a quality improvement perspective
Abstract Background Pharmaceutical companies do not sell formulations for all diseases; thus, healthcare workers have to treat some diseases by concocting in-hospital preparations. An example is the high-concentration 2% cyclosporine A (CyA) ophthalmic solution. Utilizing a filter in sterility opera...
Main Authors: | Masakazu Ozaki, Toshihiko Kobayashi, Aki Fujinaga, Mitsuaki Nishioka, Kyoko Shikichi, Satoshi Okano, Yasuhito Sakai, Sayumi Fujii, Nobuaki Matsui, Miwako Takasago, Naoto Okada, Takahiro Yamasaki, Takashi Kitahara |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2023-12-01
|
Series: | Journal of Pharmaceutical Health Care and Sciences |
Subjects: | |
Online Access: | https://doi.org/10.1186/s40780-023-00323-9 |
Similar Items
-
Cyclosporine-Associated Leukoencephalopathy in a Case of Sympathetic Ophthalmitis
by: Mizuki Tagami, et al.
Published: (2016-01-01) -
Real-World Treatment Patterns Of Cyclosporine Ophthalmic Emulsion And Lifitegrast Ophthalmic Solution Among Patients With Dry Eye
by: White DE, et al.
Published: (2019-11-01) -
Stability and Safety Traits of Novel Cyclosporine A and Tacrolimus Ophthalmic Galenic Formulations Involved in Vernal Keratoconjunctivitis Treatment by a High-Resolution Mass Spectrometry Approach
by: Daniele Giovanni Ghiglioni, et al.
Published: (2020-04-01) -
Cyclosporine A (0.05%) Ophthalmic Gel in the Treatment of Dry Eye Disease: A Multicenter, Randomized, Double-Masked, Phase III, COSMO Trial
by: Peng W, et al.
Published: (2022-09-01) -
Ophthalmic rosacea – etiology, pathogenesis, new approaches to the therapy
by: T. A. Chekhova, et al.
Published: (2016-07-01)